Guangxin Xia

USPTO Granted Patents = 11 (Patent Applications = 16)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 24)

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 5(Granted Patents)

Company Filing History:

9 out of 11

Shanghai Pharmaceuticals Holding Co., Ltd.

patents

4 out of 257

Mitsubishi Tanabe Pharma Corporation

patents

1 out of 1

Shanghai Pharmaceuticals Holding Cd., Ltd.

patent

4. 1 out of 1

Shanghai Pharmaceuticals Holdings Co., Ltd.

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11578074 - Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application (2023-02-14),

2. 10988476 - Substituted pyrimidines as cyclin-dependent kinase inhibitors (2021-04-27),

3. 10870627 - Salt of quinazoline derivative, preparation method therefor and application thereof (2020-12-22),

4. 10828305 - Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use (2020-11-10),

5. 10662186 - Substituted pyrimidines as cyclin-dependent kinase inhibitors (2020-05-26),

6. 10519150 - Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof (2019-12-31),

7. 10155731 - Nitrogen-containing saturated heterocyclic compound (2018-12-18),

8. 9556159 - Renin inhibitor (2017-01-31),

9. 9371292 - Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof (2016-06-21),

10. 9278944 - Nitrogen-containing saturated heterocyclic compound (2016-03-08),

11. 8975252 - Morpholine derivative (2015-03-10),

Title: **Innovations of Inventor Guangxin Xia**

Introduction

Guangxin Xia, a prolific inventor based in Shanghai, China, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 11 patents. His work focuses primarily on developing innovative compounds that target specific enzymes associated with various cancers, showcasing his commitment to advancing medical research and treatment options.

Latest Patents

Xia's latest patents include groundbreaking inventions such as a nitrogenous heterocyclic compound and its preparation method. This compound exhibits high inhibitory activity against the ErbB2 tyrosine kinase and shows potential in treating human breast cancer and gastric cancer cells with elevated ErbB2 expression. Additionally, his work on substituted pyrimidines emphasizes their role as cyclin-dependent kinase inhibitors, providing a promising avenue for cancer treatment.

Career Highlights

Throughout his career, Guangxin Xia has collaborated with notable firms such as Shanghai Pharmaceuticals Holding Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. His work in these organizations has significantly impacted the pharmaceutical landscape, honing his expertise in drug development and innovation.

Collaborations

Xia has also collaborated with distinguished colleagues like Toru Iijima and Jingkang Shen. Together, they have contributed to research that enhances our understanding of targeted cancer therapies and the development of novel treatment strategies.

Conclusion

In summary, Guangxin Xia's innovative spirit and dedication to pharmaceuticals have resulted in significant advancements in cancer treatment. His patents not only reflect his technical expertise but also highlight the importance of targeted therapies in medicine, paving the way for future innovations in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.